
Outsourcing collaborations provide insight into the key drivers of market growth.
Outsourcing collaborations provide insight into the key drivers of market growth.
Understanding processes in the development and manufacture of biological drug substances is crucial to successfully navigating the clinical phases towards commercial launch, all within ever‑tightening time constraints, and regulatory frameworks.
To prepare for emerging mRNA technologies, it is necessary to adapt fill/finish and cold chain capabilities.
Although new single-use technologies offer the flexibility needed to overcome several challenges in ATMP production, there are many considerations and hurdles manufacturers must be aware of when scaling.
The complexity of the pharmaceutical product brings challenges to the transfer of information and technology between sponsors and contractors.
Can CDMOs apply lessons learned from the COVID-19 pandemic to improve sterile processing?